Severe fever with thrombocytopenia syndrome (SFTS)
is an emerging infectious disease caused by severe fever with thrombocytopenia virus (SFTSV), the Phelobovirus species in the family Bunyaviridae (1, 2) . A number of SFTS cases have been reported since the first identification of SFTSV as an etiologic agent of SFTS in 2009 in China (3) , but most of them were diagnosed retrospectively (1~7).
Although clinical symptoms and progression of SFTS vary individually, common symptoms and signs include fever, thrombocytopenia, neutropenia, hemorrhagic tendency, and multiple organ dysfunction involving gastrointestinal (GI), renal, and nervous systems (4) . Because its mortality is approximately 12% on average in China, it is essential for clinicians to recognize characteristic symptoms of SFTS although guidelines for diagnosis and treatment have yet been established (5) . Here, we describe the first clinically recognized case of SFTS in South Korea in 2013. Since the current case, more patients have been identified and diagnosed with SFTS in Korea. Kim et al. reported about the first case of SFTS in Korea. However, they did not consider SFTS when they saw the patient at first. That case was detected retrospectively after this patient was identified in Korea (7). This study protocol was reviewed and approved by the institutional review board of JNUH (2013-10-010).
A 73-year-old man, who is a farmer raising cattles, was admitted to a hospital in Jeju with worsening fever and lower back pain lasting for 5 days. The patient discovered a tick crawling on his abdomen and a crust round erythematous cutaneous lesion suspicious of tick-bite at his right axilla.
Clinicians suspected of tsutsugamushi disease at first and and intravenous immunoglobulin were found to be effective in macrophage suppression, disseminated intravascular coagulation, and thrombocytopenia, respectively, in addition to use of ribavirin for hematologic abnormalities (13, 14) .
From the most recent case of SFTS, the combination of plasma exchange and ribavirin was tried with a favorable outcome and recommended as a potential rescue therapy for rapidly progressing SFTS (15) . However, their efficacies in 
